- Home
- MDGL vs FCFS Comparison
MDGL vs FCFS Comparison
Compare MDGL & FCFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- FCFS
- Stock Information
- Founded
- MDGL 2011
- FCFS 1988
- Country
- MDGL United States
- FCFS United States
- Employees
- MDGL N/A
- FCFS N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- FCFS Other Specialty Stores
- Sector
- MDGL Health Care
- FCFS Consumer Discretionary
- Exchange
- MDGL Nasdaq
- FCFS Nasdaq
- Market Cap
- MDGL 9.6B
- FCFS 6.7B
- IPO Year
- MDGL N/A
- FCFS 1991
- Fundamental
- Price
- MDGL $420.19
- FCFS $154.35
- Analyst Decision
- MDGL Strong Buy
- FCFS Strong Buy
- Analyst Count
- MDGL 12
- FCFS 4
- Target Price
- MDGL $521.09
- FCFS $153.00
- AVG Volume (30 Days)
- MDGL 270.6K
- FCFS 328.7K
- Earning Date
- MDGL 11-04-2025
- FCFS 10-30-2025
- Dividend Yield
- MDGL N/A
- FCFS 1.09%
- EPS Growth
- MDGL N/A
- FCFS 24.22
- EPS
- MDGL N/A
- FCFS 6.50
- Revenue
- MDGL $515,547,000.00
- FCFS $3,388,177,000.00
- Revenue This Year
- MDGL $394.38
- FCFS $4.03
- Revenue Next Year
- MDGL $64.73
- FCFS $8.06
- P/E Ratio
- MDGL N/A
- FCFS $23.70
- Revenue Growth
- MDGL 3421.98
- FCFS 2.49
- 52 Week Low
- MDGL $201.22
- FCFS $100.24
- 52 Week High
- MDGL $463.63
- FCFS $163.01
- Technical
- Relative Strength Index (RSI)
- MDGL 44.64
- FCFS 52.19
- Support Level
- MDGL $413.82
- FCFS $150.06
- Resistance Level
- MDGL $445.06
- FCFS $163.01
- Average True Range (ATR)
- MDGL 16.35
- FCFS 4.27
- MACD
- MDGL -3.80
- FCFS -0.65
- Stochastic Oscillator
- MDGL 17.11
- FCFS 33.13
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.